ABBVIE: Q2 REPORTED AND ADJ EPS EXPECTED TO INCLUDE ACQUIRED IPR&D, MILESTONES EXPENSE OF $269 MLN PRE-TAX

 Abbvie Inc (ABBV) - Abbvie - Reported GAAP Earnings & Adjusted.

Non-GAAP Earnings for Q2 Expected to Include Acquired Ipr&d and Milestones Expense of $269 Million on Pre-tax Basis.
Full-year 2022 Adjusted Earnings per Share Guidance Range, Including Impact of Q2 2022 Acquired Ipr&d and Milestones Expense, is $13.78 - $13.98.
Q2 2022 Adjusted Earnings per Share Guidance Range, Including Impact of Q2 2022 Acquired Ipr&d and Milestones Expense, is $3.24 - $3.28.
Abbvie - 2022 Adjusted.
Diluted EPS Guidance Previously Announced, Excluded Impact of Acquired Ipr&d & Milestones Expense That May Be Incurred Beyond Q1.
Q2 Earnings per Share View $3.43 -- Refinitiv Ibes Data (analyst estimates).
FY2022 Earnings per Share View $14.01 -- Refinitiv Ibes Data (analyst estimates).

https://www.cmlviz.com/stocks/ABBV/news/b/2022/07/06/abbvie-says-q2-reported-and-adj-eps-expected-to-include-acquired-ipr-d-and-milestones-expense-of-269-mln-on-pre-tax-basis